Expression of xenobiotic-metabolizing CYPs in human pulmonary tissue

Experimental and Toxicologic Pathology

Volumn 51, Issue 4-5, 1999, Pages 412-417

  Raunio, Hannu ^a   Hakkola, J ^a   Hukkanen, J ^a   Lassila, A ^a   Paivarinta K ^a   Pelkonen, O ^a   Anttila, S ^b   Piipari, R ^b   Boobis, A ^c   Edwards, R J ^c  

^a UNIVERSITY OF OULU   (Finland)

^b FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

CYPs; Cytochrome P450; Lung; Metabolism; Pulmonary tissue; Tissue; Xenobiotics

Indexed keywords

BENZO[A]PYRENE; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; POLYCYCLIC AROMATIC HYDROCARBON; TOBACCO SMOKE; XENOBIOTIC AGENT;

CELL TYPE; CONFERENCE PAPER; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ALVEOLUS MACROPHAGE; LUNG CARCINOGENESIS; LUNG CARCINOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; XENOBIOTIC METABOLISM;

NICOTIANA TABACUM;

EID: 0032766335     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0940-2993(99)80031-1     Document Type: Conference Paper

References (49)

1. ANTTILA S, HIETANEN E, VAINIO H, et al.: Smoking and peripheral type of cancer are related to high levels of pulmonary cytochrome P450IA in lung cancer patients. Int J Cancer 1991; 47: 681-685.
2. ANTTILA S, HIRVONEN A, VAINIO H, et al.: Immunohistochemical localization of glutathione S-transferase in human lung. Cancer Res 1993; 53: 5643-5648.
3. ANTTILA S, HIRVONEN A, HUSGAFVEL-PURSIAINEN K, et al.: Combined effect of CYP1A1 inducibility and GSTM1 polymorphism on histological type of lung cancer. Carcinogenesis 1994; 15: 1133-1135.
4. ANTTILA S, HUKKANEN J, HAKKOLA J, et al.: Expression and localization of CYP3A4 and CYP3A5 in human lung. Am J Respir Cell Mol Biol 1997; 16: 242-249.
5. AUTRUP H: Carcinogen metabolism in cultured human tissues and cells. Carcinogenesis 1990; 11: 707-712.
6. BARON J, VOIGT JM: Localization, distribution, and induction xenobiotic-metabolizing enzymes and aryl hydrocarbon hydroxylase activity within lung. Pharmacol Ther 1990; 47: 419-445.
7. COSMA GN, TONIOLO P, CURRIE D, et al.: Expression of CYP1A1 gene in peripheral lymphocytes as a marker of exposure in railroad workers. Cancer Epidemiol Biomarkers Prev 1992; 1: 137-142.
8. CZERWINSKI M, MCLEMORE TL, GELBOIN HV, GONZALEZ F J: Quantitation of CYP2B7, CYP4B1, and CYPOR messenger RNAs in normal human lung and lung tumors. Cancer Res 1994; 54: 1085-1091.
9. D'ERRICO A, TAIOLI E, CHEN X, VINEIS P: Genetic metabolic polymorphisms and the risk of cancer: a review of the literature. Biomarkers 1996; 1: 149-173.
10. DENISSENKO MF, PAO A, TANG M, PFEIFER GP: Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 1996; 274: 430-432.
11. DÖHR O, SINNING R, VOGEL C, et al.: Effect of transforming growth factor-b1 on expression of aryl hydrocarbon receptor and genes of Ah gene battery:clues for independent down-regulation in A549 cells. Mol Pharmacol 1997; 51: 703-710.
12. GODSCHALK RWL, MAAS LM, VAN ZANDWIJK N, et al.: Differences in aromatic-DNA adduct levels between alveolar macrophages and subpopulations of white blood cells from smokers. Carcinogenesis 1998; 19: 819-825.
13. GONZALEZ FJ, GELBOIN HV: Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 1994; 26: 165-183.
14. GUENGERICH FP: Purification and characterization of xenobiotic-metabolizing enzymes from lung tissue. Pharmacol Ther 1990; 45: 299-307.
15. GUENGERICH FP: Bioactivation and detoxication of toxic and carcinogenic chemicals. Drug Metab Dispos 1993; 21: 1-6.
16. GUENGERICH FP: Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity. Toxicol Lett 1994; 70: 133-138.
17. GUIDICE J-M L, MAREZ D, SABBAGH N, et al.: Evidence for CYP2D6 expression in human lung. Biochem Biophys Res Commun 1997; 241: 79-85.
18. HAKKOLA J, PASANEN M, PELKONEN O, et al.: Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta and cultured cells. Carcinogenesis 1997; 18: 391-397.
19. HARRIS CC: Human tissues and cells in carcinogenesis research. Cancer Res 1987; 47: 1-10.
20. HUANG Z, FASCO MJ, SPIVACK S, KAMINSKY LS: Comparisons of CYP2D messenger RNA splice variant profiles in human lung tumors and normal tissues. Cancer Res 1997; 57: 2589-2592.
21. HUKKANEN J, HAKKOLA J, ANTTILA S, et al.: Detection of mRNA encoding xenobiotic-metabolizing cytochrome P450s in human broncho-alveolar macrophages and peripheral blood lymphocytes. Mol Carcinog 1997; 20: 224-230.
22. IARC: Iarc Monographs on the Carcinogenic Risk of Chemicals to Humans. Volume 38: Tobacco Smoking. Lyon: IARC 1986; p.83.
23. JACQUET M, LAMBERT V, TODARO A, KREMERS P: Mitogen-activated lymphocytes: a good model for characterising lung CYP1A1 activity. Eur J Epidemiol 1997; 13: 177-183.
24. JANARDAN SK, LOWN KS, SCHMIEDLIN-REN P, et al.: Selective expression of CYP3A5 and not CYP3A4 in human blood. Pharmacogenetics 1996; 6: 379-385.
25. 1 activation in human lung. Toxicol Appl Pharmacol 1997; 144: 88-95.
26. KIKKAWA Y: Diverse role of pulmonary cytochrome P-450 monooxygenase. Lab Invest 1992; 67: 535-539.
27. KIVISTÖ KT, FRITZ P, LINDER A, et al.: Immunohistochemical localization of cytochrome P450 3A in human pulmonary carcinomas and normal bronchial tissue. Histochemistry 1995a; 103: 25-29.
28. KIVISTÖ KT, LINDER A, FRIEDEL G, et al.: Immunohistochemical localization of cytochrome P450 2E1 in human pulmonary carcinoma and normal bronchial tissue. Virchows Arch 1995b; 426: 243-247.
29. KIVISTÖ KT, GRIESE E-U, FRITZ P, et al.: Expression of cytochrome P4503A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumors. Naunyn-Schmiedeberg Arch Pharmacol 1996; 353: 207-212.
30. KIVISTÖ KT, GRIESE E-U, STUVEN T, et al.: Analysis of CYP2D6 expression in human lung: implications for the association between CYP2D6 activity and susceptibility to lung cancer. Pharmacogenetics 1997; 7: 295-302.
31. LAW MR: Genetic predisposition to cancer. Br J Cancer 1990; 61: 195-206.
32. LI D, WANG M, CHENG L, et al.: In vitro induction of benzo(a)pyrene diol epoxide-DNA adducts in peripheral lymphocytes as a susceptibility marker for human lung cancer. Cancer Res 1996; 56: 3638-3641.
33. MCLEMORE TL, ADELBERG S, LIU MC, et al.: Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J Natl Cancer Inst 1990; 83: 1333-1339.
34. NELSON DR, KOYMANS L, KAMATAKI T, et al.: P450 super-family: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1-42.
35. NHAMBURO PT, GONZALEZ FJ, MCBRIDE OW, et al.: Identification of a new P450 expressed in human lung: complete cDNA sequence, cDNA-directed expression, and chromosome mapping. Biochemistry 1989; 28: 8060-8066.
36. NHAMBURO PT, KIMURA S, MCBRIDE OW, et al.: The human CYP2F gene family: identification of a cDNA encoding a new cytochrome P450, cDNA-directed expression, and chromosome mapping. Biochemistry 1990; 29: 5491-5499.
37. RAUCY JL, SCHULTZ ED, WESTER MR, et al.: Human lymphocyte cytochrome P450 2E1, a putative marker for alcohol-mediated changes in hepatic chlorzoxazone activity. Drug Metab Dispos 1997; 25: 1429-1435.
38. RAUNIO H, PASANEN M, MÄENPÄÄ J, et al.: Expression of extrahepatic cytochrome P450 in humans. In: Advances in Drug Metabolism in Man, edited by G. M. PACIFICI and G. N. FRACCHIA. Luxembourg: European Commission, Office for Official Publications of the European Communities 1995; p. 234-287.
39. ROJAS M, CAMUS A-M, ALEXANDROV K, et al.: Stereoselective metabolism of (-)-benzo[a]pyrene-7,8-diol by human lung microsomes and peripheral blood lymphocytes: effects of smoking. Carcinogenesis 1992; 13: 929-933.
40. RUMSBY PC, YARDLEY-JONES A, ANDERSON D, et al.: Detection of CYP1A1 mRNA levels and CYP1A1 Msp 1 polymorphisms as possible biomarkers of exposure and susceptibility in smokers and non-smokers. Teratog Carcinog Mutagen 1996; 16: 65-74.
41. SHIMADA T, HAYES CL, YAMAZAKI H, et al.: Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res 1996a; 56: 2979-2984.
42. SHIMADA T, YAMAZAKI H, MIMURA M, et al.: Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal livers and adult lungs. Drug Metab Dispos 1996b; 24: 515-522.
43. Song B-J, Veech RL, Saenger P: Cytochrome P450IIE1 is elevated in lymphocytes from poorly controlled insulin-dependent diabetics. Clin Endocrinol Metab 1990; 44: 1036-1040.
44. VAN SCHOOTEN FJ, HILLEBRAND MJX, VAN LEEUWEN FE, et al.: Polycyclic aromatic hydrocarbon-DNA adducts in white blood cells from lung cancer patients: no correlation with adduct levels in lung. Carcinogenesis 1992; 13: 987-993.
45. VANDEN HEUVEL JP, CLARK GC, THOMPSON CL, et al.: CYP1A1 mRNA levels as a human exposure marker: use of quantitative polymerase chain reaction to measure CYP1A1 expression in human peripheral blood lymphocytes. Carcinogenesis 1993; 14: 2003-2006.
46. WHEELER CW, WRIGHTON SA, GUENTHNER TM: Detection of human lung cytochrome P450 that are immunochemically related to cytochrome P450IIE1 and cytochrome P450IIIA. Biochem Pharmacol 1992; 44: 911-917.
47. WHEELER CW, GUENTHNER TM: Cytochrome P-450-dependent metabolism of xenobiotics in human lung. J Biochem Toxicol 1991; 6: 163-169.
48. WIENCKE JK, KELSEY KT, VARKONYI A, et al.: Correlation of DNA adducts in blood mononuclear cells with tobacco carcinogen-induced damage in human lung. Cancer Res 1995; 55: 4910-4914.
49. WILLEY JC, COY E, BROLLY C, et al.: Xenobiotic metabolism gene expression in human bronchial epithelial and alveolar macrophage cells. Am J Respir Cell Mol Biol 1996; 14: 262-271.